Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Medical Marijuana Program Connection
JANUARY 2, 2024
.–(BUSINESS WIRE)—- $LBPH #DEEs–Longboard Pharmaceuticals, Inc. Read More
Let's personalize your content